Extended duration dual antiplatelet therapy and mortality: A systematic review and meta-analysis

The Lancet

Volumn 385, Issue 9970, 2015, Pages 792-798

  Elmariah, Sammy ^a,b   Mauri, Laura ^a,b   Doros, Gheorghe ^b,c   Galper, Benjamin Z ^a   O'Neill, Kelly E ^a   Steg, Philippe Gabriel ^d,e,f   Kereiakes, Dean J ^g   Yeh, Robert W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ANTICOAGULANT THERAPY; ARTICLE; BAYES THEOREM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COCHRANE LIBRARY; DEATH; DRUG EFFECT; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NON CARDIOVASCULAR DEATH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; EPIDEMIOLOGY; LONG TERM CARE; MORTALITY;

CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; HUMANS; LONG-TERM CARE; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84961289919     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62052-3     Document Type: Article

References (25)

1. DL Bhatt, KA Fox, W Hacke the CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
2. OR Benavente, RG Hart, LA McClure, JM Szychowski, CS Coffey, LA Pearce the SPS3 Investigators Effects of clopidogrel added to aspirin in patients with recent lacunar stroke N Engl J Med 367 2012 817 825
3. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (in press).
4. JP Higgins, DG Altman, PC Gøtzsche the Cochrane Bias Methods Group the Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
5. MK Parmar, V Torri, L Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
6. AA Tsiatis The asymptomatic joint distribution of the efficient scores test for the proportional hazards model calculated over time Biometrika 68 1981 311 315
7. DJ Spiegelhalter, JP Myles, DR Jones, KR Abrams Bayesian methods in health technology assessment: a review Health Technol Assess 4 2000 1 130
8. D Lunn, D Spiegelhalter, A Thomas, N Best The BUGS project: evolution, critique and future directions Stat Med 28 2009 3049 3067
9. JP Higgins, SG Thompson, JJ Deeks, DG Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
10. JJ Belch, J Dormandy, GM Biasi et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial J Vasc Surg 52 2010 825 833
11. A Colombo, A Chieffo, A Frasheri et al. Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial J Am Coll Cardiol 64 2014 2086 2097
12. SJ Connolly, J Pogue, RG Hart the ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
13. F Feres, RA Costa, A Abizaid the OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
14. HC Gwon, JY Hahn, KW Park et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
15. BK Kim, MK Hong, DH Shin the RESET Investigators A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
16. SR Steinhubl, PB Berger, JT Mann 3rd the CREDO Investigators Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
17. M Valgimigli, G Campo, M Monti the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
18. S Yusuf, F Zhao, SR Mehta, S Chrolavicius, G Tognoni, KK Fox the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
19. JP Collet, J Silvain, O Barthélémy the for the ARCTIC investigators Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Lancet 2014 published online July 15. http://dx.doi.org/10.1016/S0140-6736(14)60612-7
20. CW Lee, JM Ahn, DW Park et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial Circulation 129 2014 304 312
21. AS Go, D Mozaffarian, VL Roger the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2014 update: a report from the American Heart Association Circulation 129 2014 e28 292
22. JA Spertus, R Kettelkamp, C Vance et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 113 2006 2803 2809
23. PM Ho, ED Peterson, L Wang et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome JAMA 299 2008 532 539
24. DB Spoon, PJ Psaltis, M Singh et al. Trends in cause of death after percutaneous coronary intervention Circulation 129 2014 1286 1294
25. PG Steg, AP Cheong Death (after percutaneous coronary intervention) is no longer what it used to be Circulation 129 2014 1267 1269